The most appropriate dialysate composition is one of the central topics in dialysis treatment. The prescription of a certain dialysate composition could change in order to obtain not only an adequate blood purification but also a high tolerability. Sodium balance represents the cornerstone of cardiovascular stability and good blood pressure control. The goal of dialysis is to remove the amount that has accumulated in the interdialysis period. Potassium removal is adequate when hyperkaliemia is avoided. Bicarbonate in dialysate should be personalized in order to avoid acidosis and end-dialysis excessive alkalosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000129748 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Probiotic treatment induces changes in intestinal microbiota but does not alter SCFA levels in peritoneal dialysis patients-a randomized, placebo-controlled trial.
Sci Rep
December 2024
Department of Nephrology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, China.
The gut microbiota alterations interact with the pathogenesis and progression of chronic kidney disease (CKD). Probiotics have received wide attention as a potential management in CKD. We investigated the effects of Lactobacillus paracasei N1115 (LP N1115) on intestinal microbiota and related short-chain fatty acids (SCFAs) in end stage kidney disease patients on peritoneal dialysis (PD) in a single-center, prospective, randomized, double-blind, placebo-controlled study.
View Article and Find Full Text PDFExploring Biomarkers for Excess Extracellular Fluid in the Context of Physical Function in Chronic Kidney Disease Patients.
J Pers Med
November 2024
Division of Nephrology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Republic of Korea.
: Fluid overload is an important risk factor for protein-energy wasting, which could lead to poor outcomes, such as higher morbidity and mortality, in patients with chronic kidney disease (CKD). This study aimed to validate the possible myokine as a biomarker of volume status in patients with non-dialysis CKD. : In total, 151 patients with CKD were enrolled from a single medical center.
View Article and Find Full Text PDFSynthesis of triangular lignin photonic crystal nanoparticles: Investigating solvent effects and dialysis optimization.
Int J Biol Macromol
December 2024
Composites and Nanocomposites Center, Moroccan Foundation for Advanced Science, Innovation and Research, Rabat Design Center, Rue Mohamed El Jazouli, Madinat El Irfane, Rabat 10100, Morocco; Mohammed VI Polytechnic University, Lot 660 Hay Moulay Rachid, 43150 Ben Guerir, Morocco. Electronic address:
Article Synopsis
- Researchers have developed a new method to create triangular lignin nanoparticles (LNPs), improving on traditional spherical shapes, for potential use in optical applications.
- This green technique employs solvent shifting and acid precipitation, allowing for controlled structural changes in the nanoparticles.
- The resulting LNPs exhibit good hydrophobic properties, excellent UV-blocking efficiency, and long-term stability in aqueous suspensions, making them promising for applications like sunscreen.
Thromboembolic Events in the Hemodialysis Setting: Understanding Risk Profiles and Cumulative Incidences to Inform Clinical Trial Design.
J Am Heart Assoc
December 2024
Arbor Research Collaborative for Health Ann Arbor MI USA.
Background: People with kidney failure have a high risk of cardiovascular morbidity/death, including thromboembolic events. Factor XIa inhibitors are a new class of anticoagulants in development that may offer antithrombotic benefits with a lower risk of incremental bleeding events than traditional therapies. We investigated major adverse vascular events (MAVEs), a relevant composite outcome for testing novel antithrombotic agents, in a large cohort of patients on hemodialysis, to better understand the key requirements to adequately design a phase 3 trial.
View Article and Find Full Text PDFAtherothrombotic Outcomes After Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes: A Territory-Wide Retrospective Cohort Study.
J Am Heart Assoc
December 2024
Department of Medicine, Queen Mary Hospital The University of Hong Kong Hong Kong SAR China.
Background: This study compared the risks of atherothrombotic major adverse cardiovascular events in patients with type 2 diabetes taking SGLT2 (sodium-glucose cotransporter 2) inhibitors to those taking DPP-4 (dipeptidyl peptidase-4) inhibitors.
Methods And Results: All adult patients (≥18 years of age) with type 2 diabetes and newly prescribed with SGLT2 inhibitors or DPP-4 inhibitors across all public hospitals in Hong Kong between January 2015 and December 2019 were included. Patients were propensity matched in a 1:1 ratio using a caliper distance of 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!